NIAGARA - New Standard for Muscle Invasive Bladder Cancer with Neoadj Chemo & Periop Durvalumab

Drs. Rahul and Rohit Gosain dived deep into the rapidly evolving landscape of bladder cancer treatment. Joined by esteemed medical oncology colleagues Dr. Karine Tawagi and Dr. Petros Grivas, along with urologists Dr. Joshua Meeks and Dr. Neal Shore, the discussion centers around the groundbreaking NIAGARA trial and the new standard of care involving Durvalumab in muscle-invasive bladder cancer. Key topics included: • The latest findings from the NIAGARA trial and its implications for patient care. • The role of neoadjuvant chemotherapy along with immunotherapy, and the importance of multidisciplinary collaboration in treatment planning. • Insights into patient outcomes, including event-free survival and overall survival rates. • The significance of ctDNA and pathological complete response (pCR) in assessing treatment effectiveness. • The evolving conversation around treatment options for patients with varying renal function. Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ Tune in to learn how these advancements are shaping the future of bladder cancer treatment and improving patient outcomes. Don't forget to like, subscribe, and share your thoughts in the comments!